Clinical trial
A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing's Sarcoma
NCT05440786 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing's Sarcoma
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- September 20, 2022
- Completion date
- December 31, 2026
- Enrollment
- 46 (actual)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.